Nome |
# |
Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday, file e383531e-d485-15e8-e053-a505fe0a3de9
|
343
|
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer, file e383532e-f07e-15e8-e053-a505fe0a3de9
|
198
|
Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients, file e3835315-c032-15e8-e053-a505fe0a3de9
|
127
|
Pfizer-BioNtech COVID-19 vaccine in gynecologic oncology patients. A prospective cohort study, file e383532d-bd3b-15e8-e053-a505fe0a3de9
|
125
|
Immunotherapy in HER2-positive breast cancer. state of the art and future perspectives, file e3835326-cb79-15e8-e053-a505fe0a3de9
|
119
|
Progesterone therapy in endometrial cancer, file e3835318-be6f-15e8-e053-a505fe0a3de9
|
110
|
Fertility preservation in gynaecologic cancers, file e383531a-7a28-15e8-e053-a505fe0a3de9
|
110
|
Triple negative breast cancer: new perspectives for targeted therapies, file e3835311-d524-15e8-e053-a505fe0a3de9
|
109
|
Fertility preservation in ovarian tumours, file e3835323-0571-15e8-e053-a505fe0a3de9
|
105
|
Comparison of anogenital distance and correlation with vulvo-vaginal atrophy: a pilot study on premenopausal and postmenopausal women, file e3835321-8251-15e8-e053-a505fe0a3de9
|
101
|
RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition, file e3835322-d442-15e8-e053-a505fe0a3de9
|
100
|
Endometriosis and pregnancy. a single institution experience, file e3835324-2a1f-15e8-e053-a505fe0a3de9
|
100
|
Niraparib in ovarian cancer. results to date and clinical potential, file e3835317-a6f5-15e8-e053-a505fe0a3de9
|
97
|
Pembrolizumab in programmed death ligand 1-positive endometrial cancer, file e3835318-a20d-15e8-e053-a505fe0a3de9
|
96
|
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment, file e3835315-bd1f-15e8-e053-a505fe0a3de9
|
93
|
Investigating patterns of immune interaction in ovarian cancer: probing the O-glycoproteome by the macrophage galactose-like C-type Lectin (MGL), file e3835327-9c19-15e8-e053-a505fe0a3de9
|
82
|
Innovations in the treatment of ovarian cancer. Analysis of the therapeutic development: from platinum to immunotherapy [Innovazioni terapeutiche nel trattamento del tumore ovarico. Analisi del percorso per lo sviluppo terapeutico: dal platino all’immunoterapia], file e3835323-6c60-15e8-e053-a505fe0a3de9
|
80
|
Evaluation of parametrial status in locally advanced cervical cancer patients after neoadjuvant chemotherapy: a prospective study on diagnostic accuracy of three-dimensional transvaginal ultrasound, file e3835326-6a8b-15e8-e053-a505fe0a3de9
|
80
|
The age-adjusted Charlson comorbidity index as a predictor of survival in surgically treated vulvar cancer patients, file e383531e-9aa2-15e8-e053-a505fe0a3de9
|
78
|
Unexpected Metastasis of High Grade Serous Ovarian Cancer to Breast: Case Report and Literature Review, file e3835323-d3bc-15e8-e053-a505fe0a3de9
|
76
|
Adjuvant therapy for early uterine high-grade leiomyosarcoma, file e3835322-ddf2-15e8-e053-a505fe0a3de9
|
68
|
Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer, file e3835322-acbf-15e8-e053-a505fe0a3de9
|
67
|
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting, file e3835322-d440-15e8-e053-a505fe0a3de9
|
59
|
Breast cancer risk after ovarian stimulation for In vitro fertilization, file e3835315-d417-15e8-e053-a505fe0a3de9
|
57
|
Recurrent mantle cell lymphoma in the uterine cervix: a case report, file e3835327-bd1c-15e8-e053-a505fe0a3de9
|
56
|
null, file e3835315-f71b-15e8-e053-a505fe0a3de9
|
55
|
Fertility preservation and reproductive health in patients undergoing hematopoietic stem cell transplantation, file e3835326-cb67-15e8-e053-a505fe0a3de9
|
52
|
Role of circulating biomarkers in platinum-resistant ovarian cancer, file e383532d-e17d-15e8-e053-a505fe0a3de9
|
52
|
Uterine irradiation as a determinant of infertility and pregnancy losses in young cancer survivors, file e3835326-e6de-15e8-e053-a505fe0a3de9
|
49
|
Targeting angiogenesis in endometrial cancer - New agents for tailored treatments, file e3835316-0faa-15e8-e053-a505fe0a3de9
|
48
|
ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies, file e3835328-40cc-15e8-e053-a505fe0a3de9
|
48
|
Ovarian cancer metastasis to the breast: a case report and review of the literature, file e3835329-3648-15e8-e053-a505fe0a3de9
|
44
|
MRI- and histologic-molecular-based radio-genomics nomogram for preoperative assessment of risk classes in endometrial cancer, file 0269f37b-d3b4-4628-81eb-bd9295688df0
|
39
|
First-line treatment with olaparib for early stage BRCA-positive ovarian cancer: may it be possible? Hypothesis potentially generating a line of research, file e3835328-40c8-15e8-e053-a505fe0a3de9
|
39
|
Immune checkpoint inhibitors: a promising choice for endometrial cancer patients?, file e383532c-65bc-15e8-e053-a505fe0a3de9
|
37
|
CT-based radiomics and deep learning for BRCA mutation and progression-free survival prediction in ovarian cancer using a multicentric dataset, file e383532f-0d7f-15e8-e053-a505fe0a3de9
|
25
|
Role of genomic and molecular biology in the modulation of the treatment of endometrial cancer. narrative review and perspectives, file 79480a16-f1c7-45de-a8d3-e17f392e1583
|
23
|
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting, file e383532e-fa2b-15e8-e053-a505fe0a3de9
|
15
|
Modified gluteal fold advancement V-Y flap for vulvar reconstruction after surgery for vulvar malignancies, file e3835313-8abb-15e8-e053-a505fe0a3de9
|
14
|
Systematic lymph node dissection during interval debulking surgery for advanced epithelial ovarian cancer. a systematic review and meta-analysis, file a97293be-6411-4595-9f8b-505a41f3c335
|
13
|
Circulating hpv dna in the management of oropharyngeal and cervical cancers: current knowledge and future perspectives, file 28d040f3-75f0-4669-9847-0444212b96d4
|
12
|
Incidence of chemotherapy (CT) induced amenorrhea in premenopausal patients (pts) with breast cancer (BC) following adjuvant anthracycline (A), cyclophosphamide (C), and taxane (T), file e3835315-d3cc-15e8-e053-a505fe0a3de9
|
10
|
Efficacy, safety, and cost-effectiveness (CE) analysis of pegfilgrastim (P) and lenograstim (L) in patients (pts) with nonmetastatic breast cancer (nmBC) receiving myelosuppressive chemotherapy (mCT)., file e3835316-0981-15e8-e053-a505fe0a3de9
|
10
|
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting, file e383532a-6618-15e8-e053-a505fe0a3de9
|
10
|
Primary prophylaxis of neutropenia in women affected by breast cancer undergoing adjuvant chemotherapy with fec 100+/- docetaxel. Comparison of efficacy and tolerability between lenograstim and pegfilgrastim, file e3835326-e2b4-15e8-e053-a505fe0a3de9
|
9
|
RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition, file e383532b-1777-15e8-e053-a505fe0a3de9
|
9
|
null, file e5e1a280-5390-4e9c-a00f-60b5a538c9cc
|
9
|
Gonadotropin-releasing hormone agonists for the preservation of ovarian function during chemotherapy., file e3835312-3f4f-15e8-e053-a505fe0a3de9
|
8
|
Breast adenomyoepithelioma: a case report with malignant proliferation of epithelial and myoepithelial elements, file e3835311-5b49-15e8-e053-a505fe0a3de9
|
7
|
Role of vacuum assisted biopsy(mammotome) in early detection of breast cancer, file e3835312-55d5-15e8-e053-a505fe0a3de9
|
7
|
Bevacizumab in ovarian cancer: state of the art and unanswered questions, file e3835316-3173-15e8-e053-a505fe0a3de9
|
7
|
OP29.03: Identification of parametria by 2D-3D ultrasound in patients with cervical cancer: new perspectives and future applications, file e3835316-dd2e-15e8-e053-a505fe0a3de9
|
7
|
The efficacy of dienogest in reducing disease and pain recurrence after endometriosis surgery. a systematic review and meta-analysis, file 10ccaf53-8907-4c04-96ee-280da4708c95
|
6
|
Immunological and clinical impact of cancer stem cells in vulvar cancer: role of CD133/CD24/ABCG2-Expressing Cells, file e3835315-7f05-15e8-e053-a505fe0a3de9
|
6
|
G-CSF related bone pain (BP) and Bv8/PK2 expression: Is there a link in breast cancer (BC) patients (pts) treated with FEC100 adjuvant chemotherapy (CT)?, file e3835316-32ef-15e8-e053-a505fe0a3de9
|
6
|
Evaluation of CA125 and HE4 diagnostic performance in hereditary and sporadic ovarian cancer, file e3835321-e27b-15e8-e053-a505fe0a3de9
|
6
|
Exosomes factory: a new strategy for antitumour vaccines, file e3835312-3645-15e8-e053-a505fe0a3de9
|
5
|
Sexual health and quality of life assessment among ovarian cancer patients during chemotherapy, file e3835315-a3c5-15e8-e053-a505fe0a3de9
|
5
|
null, file e3835315-ab82-15e8-e053-a505fe0a3de9
|
5
|
P66. Pilot Study on Subserosal and Intramural Uterine Leiomyomas and Magnetic Resonance-guided Focused Ultrasound Surgery ( MRgFUS): Are there New Predictive Indexes?, file e3835317-07cc-15e8-e053-a505fe0a3de9
|
5
|
Rucaparib. An emerging parp inhibitor for treatment of recurrent ovarian cancer, file e383531a-d20d-15e8-e053-a505fe0a3de9
|
5
|
Expression of er, pgr, her-2, and ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, file e3835325-af8c-15e8-e053-a505fe0a3de9
|
5
|
Impact of hormone receptor status and Ki-67 expression on disease-free survival in patients affected by high-risk endometrial cancer, file e3835328-7db6-15e8-e053-a505fe0a3de9
|
5
|
Therapeutic Approaches to Vulvar Cancer. A Review of Literature, file 807f300a-a629-4d90-94fe-2fb1e971b571
|
4
|
The puzzle of gynecologic neuroendocrine carcinomas: State of the art and future directions, file 8205f8ff-e67b-4d6a-9e68-9d8f4838965a
|
4
|
PROGNOSTIC VALUE OF CIRCULATING TUMOR CELLS IN PATIENTS WITH METASTATIC BREAST CANCER AND METASTATIC PROSTATE CANCER, file e3835311-d11d-15e8-e053-a505fe0a3de9
|
4
|
Improvement in Progression-Free Survival in OCEANS Bevacizumab Arm: A Critical Point of View, file e3835311-fa2e-15e8-e053-a505fe0a3de9
|
4
|
Fertility-Sparing Options in Young Women with Cervical Cancer., file e3835315-90a9-15e8-e053-a505fe0a3de9
|
4
|
Breast adenomyoepithelioma: a case report with malignant proliferation of epithelial and myoepithelial elements, file e3835315-d5fc-15e8-e053-a505fe0a3de9
|
4
|
Magnetic resonance imaging-radiomics in endometrial cancer: a systematic review and meta-analysis, file 48b733a0-3e2c-47f9-8430-8247e56e9738
|
3
|
Age-Adjusted Charlson Comorbidity Index Predicts Survival in Endometrial Cancer Patients, file afedd940-5bd5-4468-8629-d05368679c1b
|
3
|
The puzzle of gynecologic neuroendocrine carcinomas: State of the art and future directions, file e20f496c-339c-4fb3-a1a1-0a5d43434423
|
3
|
Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies, file e3835315-7039-15e8-e053-a505fe0a3de9
|
3
|
null, file e3835315-83d6-15e8-e053-a505fe0a3de9
|
3
|
Special issues in fertility preservation for gynecologic malignancies, file e3835315-b7b4-15e8-e053-a505fe0a3de9
|
3
|
Quality of life effects of ovarian suppression in the suppression of ovarian function trial, file e3835315-bbbe-15e8-e053-a505fe0a3de9
|
3
|
null, file e3835315-be68-15e8-e053-a505fe0a3de9
|
3
|
Primary endocrine therapy in older women with locally advanced breast cancer, file e3835316-097a-15e8-e053-a505fe0a3de9
|
3
|
Intraperitoneal chemotherapy in advanced ovarian cancer: old and novel questions, file e3835326-cd12-15e8-e053-a505fe0a3de9
|
3
|
The emerging role of precision medicine in the treatment of ovarian cancer, file e3835327-5770-15e8-e053-a505fe0a3de9
|
3
|
An update on current pharmacotherapy for vulvar cancer, file 4e05a791-f771-41ee-88d1-e26d40684f50
|
2
|
Sarcopenia in Breast Cancer Patients: A Systematic Review and Meta-Analysis, file a7039b5e-3b3e-4a7b-8e0b-092b8400426d
|
2
|
Capecitabine in treating patients with advanced, persistent, or recurrent cervical cancer: an active and safe option?, file d823e90f-7865-4c6c-9c24-f497fe3443e9
|
2
|
Endocrinoterapia neoadiuvante nel carcinoma della mammella localmente avanzato, file e3835311-adf7-15e8-e053-a505fe0a3de9
|
2
|
Clinical use of fertility agents and risk of breast cancer: a recent update for an old problem, file e3835311-d607-15e8-e053-a505fe0a3de9
|
2
|
[Breast carcinoma in young women]., file e3835312-1b51-15e8-e053-a505fe0a3de9
|
2
|
Investigating molecular profiles of ovarian cancer: an update on cancer stem cells., file e3835313-7e32-15e8-e053-a505fe0a3de9
|
2
|
null, file e3835315-83d3-15e8-e053-a505fe0a3de9
|
2
|
Epistaxis in Weekly Paclitaxel Regimen: Is it Really Related to Schedule?, file e3835315-b980-15e8-e053-a505fe0a3de9
|
2
|
Toxicity of weekly liposomial doxorubicin and pavclitaxel in metastatic breast cancer (MBC). 24 months update, file e3835315-e967-15e8-e053-a505fe0a3de9
|
2
|
MODIFIED GLUTEAL FOLD ADVANCEMENT V-Y FLAP FOR VULVAR RECONSTRUCTION AFTER SURGERY FOR VULVAR MALIGNANCIES., file e3835315-ecb7-15e8-e053-a505fe0a3de9
|
2
|
The role of BMI and age in chemotherapy-induced amenorrhea (CIA) in premenopausal breast cancer (PBC) patients treated with adjuvant FEC100 with or without docetaxel (D), file e3835316-32f0-15e8-e053-a505fe0a3de9
|
2
|
Update on fertility-sparing treatment in primary and recurrent endometrial cancer, file e3835318-008a-15e8-e053-a505fe0a3de9
|
2
|
Paclitaxel and pazopanib in ovarian cancer, file e383531b-d921-15e8-e053-a505fe0a3de9
|
2
|
Complete remission of cerebral endometriosis with dienogest: a case report, file e383531b-d990-15e8-e053-a505fe0a3de9
|
2
|
Fertility drugs and breast cancer risk, file e3835321-ccde-15e8-e053-a505fe0a3de9
|
2
|
null, file e3835326-cb76-15e8-e053-a505fe0a3de9
|
2
|
Fertility and reproduction in breast cancer patients, file e3835326-cd0c-15e8-e053-a505fe0a3de9
|
2
|
Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial, file e3835326-e6e2-15e8-e053-a505fe0a3de9
|
2
|
Metachronous and synchronous cancers in patients with neuroendocrine tumors, file e3835326-e6e6-15e8-e053-a505fe0a3de9
|
2
|
Totale |
3.450 |